Attention Investors: Did You Lose Money on Sangamo Therapeutics Inc?
Contact Levi & Korsinsky for an Ongoing Investigation into SGMO
New York, NY / ACCESSWIRE / January 2, 2025 –
Levi & Korsinsky, a prominent law firm, has initiated an investigation into Sangamo Therapeutics, Inc. (“Sangamo Therapeutics, Inc.”) (NASDAQ:SGMO) over potential breaches of federal securities laws. The investigation comes on the heels of Sangamo’s recent announcement on December 30, 2024, indicating that Pfizer, their partner in the development of hemophilia A gene therapy giroctocogene fitelparvovec, will be returning the development and commercialization rights to Sangamo after opting out of pursuing commercialization of the asset, which is currently in phase 3 of development.
As an investor in Sangamo Therapeutics Inc., it can be concerning to hear news of a significant setback in the development of a key therapy. The decision by Pfizer to relinquish the rights to giroctocogene fitelparvovec raises questions about the future prospects of the therapy and ultimately the financial implications for investors. This move may lead to a decline in the stock value of Sangamo Therapeutics Inc., potentially resulting in losses for shareholders.
Investors who have suffered losses in Sangamo Therapeutics Inc. may be eligible to participate in a class action lawsuit to seek compensation for their losses. Levi & Korsinsky is actively investigating the situation and is committed to holding Sangamo accountable for any potential violations of federal securities laws.
How Does This Affect Me?
As an investor in Sangamo Therapeutics Inc., the decision by Pfizer to withdraw from the collaboration on giroctocogene fitelparvovec could lead to negative consequences for your investment. It is important to stay informed about developments in the situation and consider seeking legal recourse if you have suffered financial losses as a result of this decision.
How Does This Affect the World?
The decision by Pfizer to halt the commercialization of giroctocogene fitelparvovec could have broader implications for the world of biotechnology and medical research. It highlights the uncertainties and risks associated with drug development partnerships and the potential impact on patients awaiting innovative therapies. This setback underscores the challenges and complexities of bringing new treatments to market and the need for transparency and accountability in the pharmaceutical industry.
Conclusion
The ongoing investigation into Sangamo Therapeutics Inc. by Levi & Korsinsky serves as a reminder of the risks and uncertainties inherent in the world of investing, particularly in the biotechnology sector. As developments unfold, it is crucial for investors to stay informed and take appropriate action to protect their interests. The decision by Pfizer to relinquish the rights to giroctocogene fitelparvovec not only affects individual investors but also raises broader questions about the future of medical research and innovation.
